Polysaccharides (e.g., Cellulose, Etc.) Patents (Class 424/488)
  • Patent number: 11103601
    Abstract: Disclosed is a lymph targeting nuclear magnetic contrast agent using a brown algae polysaccharide as a carrier, and a preparation method and a use thereof. A macromolecular contrast agent with good water solubility was prepared by using the brown algae polysaccharide as the carrier, using mannose or mannose derivatives as a mannose receptor (MBP) recognition group, and using a paramagnetic metal ion chelate as a nuclear magnetic resonance imaging group. The binding capacity of lymphoid tissue was improved. The mannose or mannose derivative group introduced into the synthesized contrast agent molecule achieves the goal of binding to the enriched mannose receptors in the lymphoid tissues. At the same time, after the contrast agent is injected subcutaneously, both lymph vessels and lymph nodes were clearly visualized under MRI scanning.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: August 31, 2021
    Assignee: OCEAN UNIVERSITY OF CHINA
    Inventors: Tao Jiang, Shengbiao Wan, Wei Shang, Nan Zhang, Mingliang Zhao
  • Patent number: 11096412
    Abstract: A nicotine pouch composition is disclosed, the pouch composition comprising free-base nicotine and having a water content of at least 15% by weight of said pouch composition. Furthermore, an oral nicotine pouch product comprising the pouch composition and a method for manufacturing the oral nicotine pouch product is disclosed.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: August 24, 2021
    Inventors: My Ly Lao Stahl, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen, Bine Hare Jakobsen
  • Patent number: 11083684
    Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: August 10, 2021
    Assignee: ALLERGAN INDUSTRIE, SAS
    Inventors: Gabriel N. Njikang, Xiaojie Yu, Futian Liu, Nicholas J. Manesis
  • Patent number: 11061033
    Abstract: A Fe(II)- and Ca+2-chelated alginate/gelatin conjugate.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: July 13, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Abhinav Acharya, Steven R. Little, Tatum V. Tarin
  • Patent number: 11040066
    Abstract: The present disclosure relates to topical compositions comprising water, solvent, thickener, preservative and conditioning agent wherein the composition has a viscosity approximately in the range 200-6000 cP at 25° C. following exposure to gamma radiation, to use of the composition in a dressing and the use of compositions and dressings in treatment or prophylaxis of burns.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: June 22, 2021
    Assignee: Safeguard Medical Holdco, LLC
    Inventor: Mark Lait
  • Patent number: 11006659
    Abstract: A fortified date fruit product includes date fruit sugar and one or more mineral phosphate nanostructures. The mineral phosphate nanostructures can be selected from one or more of calcium phosphate, zinc phosphate, and iron phosphate nanostructures, among others. The mineral phosphate nanostructures can have a particle size ranging from about 5 nm to about 100 nm, e.g., about 5 nm to about 20 nm, about 50 nm to about 100 nm, and about 75 nm to about 100 nm.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: May 18, 2021
    Assignee: KING SAUD UNIVERSITY
    Inventors: Ali Abdullah Alshatwi, Jegan Athinarayanan, Periasamy Vaiyapuri Subbarayan
  • Patent number: 11000626
    Abstract: Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: May 11, 2021
    Assignee: ALLERGAN INDUSTRIE, SAS
    Inventors: Futian Liu, Xiaojie Yu, Jessamine P. Winer-Jones, Nicholas J. Manesis, Hengli Liu, Gabriel Njikang, Athene Wan Chie Chan
  • Patent number: 10994013
    Abstract: Provided is a dosage form for delivery of a therapeutic agent comprising a polymer matrix comprising arabinogalactan and a therapeutic agent uniformly dispersed in said polymer matrix. In some embodiments, the dosage form is selected from the group consisting of a microsphere, a nanosphere, a powder, a tablet, a film or a pellet enclosed in a capsule. Also provided are methods for preparing the dosage form.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: May 4, 2021
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Kalpana N. Thakare, David B. Lebo
  • Patent number: 10980887
    Abstract: The present invention relates to a method for providing an embedded mammalian cell, comprising the steps of providing an alginate sulfate in aqueous solution; reacting the alginate sulfate to form a hydrogel in a gelation step, providing a precursor cell, and embedding the precursor cell in the sulfated alginate hydrogel in an embedding step, thus yielding an sulfated alginate hydrogel embedded cell. The invention further relates to sulfated alginate hydrogels, and cellular grafts comprising a mammalian cell embedded in sulfated alginate hydrogel.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 20, 2021
    Assignee: ETH ZURICH
    Inventors: Marcy Zenobi-Wong, Gemma Palazzolo, Rami Mhanna, Jana Becher, Stefanie Moller, Matthias Schnabelrauch
  • Patent number: 10973760
    Abstract: Instantly dissolving buccal films comprising certain pH modifiers, film formers, film modifiers, and solubilizing agents are provided. Methods of providing the buccal film to enhance the dissolution and bioavailability of low solubility basic drugs, such as dapoxetine hydrochloride, in a subject are also provided.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: April 13, 2021
    Assignee: King Abdulaziz University
    Inventors: Shaimaa M. Badr-Eldin, Hibah M. Aldawsari, Abdelsattar Omar
  • Patent number: 10967097
    Abstract: A novel hydrogel wound dressing therapy and methods for making the same. The novel methods comprise forming two biopolymers, chitosan and hyaluronic acid, together into a wound dressing with inherent ability to enhance wound closure. The novel composition of the subject invention comprises cross-linked chitosan/hyaluronic acid hydrogels manufactured according to the methods disclosed having a specific cross-link density that results in a swelling ratio of 20 to 100. Hydrogels manufactured in accordance with the method of the invention dramatically increase healing rates and greatly improves outcomes of wound injuries.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: April 6, 2021
    Assignee: Oceanit Laboratories, Inc
    Inventors: Jacob Pollock, Joanne S. M. Ebesu, Dexter Poon
  • Patent number: 10959990
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions comprise aceclidine hydrochloride, polysorbate 80, mannitol, anhydrous hypromellose, disodium edetate dihydrate, benzalkonium chloride, sorbic acid and anhydrous sodium citrate and optionally tropicamide.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: March 30, 2021
    Assignee: PRESBYOPIA THERAPIES, INC
    Inventor: Gerald Horn
  • Patent number: 10918625
    Abstract: The present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient. Whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: February 16, 2021
    Assignee: KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
    Inventor: Sangtaek Oh
  • Patent number: 10905664
    Abstract: The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 2, 2021
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Swati Kulkarni, Bijay Kumar Padhi, Shanvas Alikunju, Rajeev Singh Raghuvanshi, Srinivas Ramchandra Sidgiddi, Anirudh Gautam
  • Patent number: 10906992
    Abstract: There is provided a method for producing a low polymerization degree cellulose ether having a less yellowish appearance and having excellent long-term storage stability through depolymerization of a high polymerization degree cellulose ether with an acid and without requiring an additive other than the acid. More specifically, there is provided a method for producing a low polymerization degree cellulose ether, including a step of depolymerizing a high polymerization degree cellulose ether with an acid to obtain a low polymerization degree cellulose ether mixture and a step of neutralizing the acid present in the low polymerization degree cellulose ether mixture, wherein ultraviolet is applied in the step of depolymerizing or between the steps of depolymerizing and neutralizing.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 2, 2021
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Taishi Kitaguchi, Akira Kitamura, Shintaro Matsusue, Mitsuhiro Yoshida
  • Patent number: 10850136
    Abstract: A blend for use in a personal care composition comprises a dialkyl amphiphilic component and an ester of a long chain branched fatty acid and a long chain branched alcohol. The blend can be pastillated and/or flaked, and can be used as the oil phase of an oil-in-water emulsion. The blend can be used in a moisturiser composition for moisturising skin.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: December 1, 2020
    Inventors: Graham Timothy Pennick, Michael Andrew Oakley, Bhaven Chavan
  • Patent number: 10815345
    Abstract: The present invention relates to a method for preparing a chitosan-based matrix (4) comprising the following steps: a) two separate chitosan porous layers (1, 2) obtained from lyophilisation of layers of one or more solutions of chitosan are provided, b) the chitosan porous layers of a) are neutralized and washed, c) a face (1a, 2a) of each chitosan porous layer is acidified with an acid, d) a fiber reinforcement member (3) is provided and positioned between the two acidified faces of the two chitosan porous layers, e) the two chitosan porous layers and the fiber reinforcement member are let to dry to obtain a matrix having the fiber reinforcement member embedded therein. The invention also relates to an implant comprising a matrix obtained according to such a method.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: October 27, 2020
    Assignee: SOFRADIM PRODUCTION
    Inventors: Aurelie Serrero, Mylene Desorme
  • Patent number: 10786601
    Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: September 29, 2020
    Assignee: TEOXANE
    Inventors: Francois Bourdon, Stephane Meunier
  • Patent number: 10772901
    Abstract: Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 15, 2020
    Assignees: UroPharma Limited, Synesis LLC
    Inventors: Howard Shapland, Scott Glickman, Christian G. Krueger, Amy B. Howell, Jess D. Reed
  • Patent number: 10744236
    Abstract: The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: August 18, 2020
    Assignee: PETVIVO HOLDINGS, INC.
    Inventor: David B. Masters
  • Patent number: 10709820
    Abstract: A method for producing a storable molded body made of bacterial cellulose and a molded body produced according to the method. A preferred method includes providing a molded body made of bacterial cellulose. Optionally, mechanically pressing the entire molded body or parts of the molded body at temperatures in the range of 10° C. to 100° C. and pressures in the range of 0.01 to 1 MPa for a pressing time of 10-200 min. Treating the molded body with a solution of 20% by weight to 50% by weight of glycerol and 50% by weight to 80% by weight of a C1-C3-alcohol/water mixture. Drying the treated molded body.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: July 14, 2020
    Assignee: BIOTRONIK AG
    Inventor: Jens Ulmer
  • Patent number: 10709787
    Abstract: The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: July 14, 2020
    Assignee: NEMYSIS LIMITED
    Inventors: Giovanna Pitarresi, Fabio Salvatore Palumbo, Gaetano Giammona
  • Patent number: 10702516
    Abstract: A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: July 7, 2020
    Assignee: Altria Client Services LLC
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke
  • Patent number: 10596192
    Abstract: This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using zinc or a zinc chelator to treat rotator cuff conditions are provided.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: March 24, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Scott M. Riester, John W. Sperling, Andre J. van Wijnen
  • Patent number: 10561607
    Abstract: Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of an active component and a quantity of a sterile gel. Methods for fabricating the compositions and using them for ophthalmic or burn-treating applications are also described.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: February 18, 2020
    Assignee: Harrow IP, LLC
    Inventor: John Scott Karolchyk
  • Patent number: 10426725
    Abstract: Rapidly dissolving self-supporting films for food or pharmaceutical use comprising: a) a filmogenic substance consisting of a maltodextrin; b) a plasticizer; c) an active principle for food or pharmaceutical use, characterized in that said films are free of hydrocolloids.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: October 1, 2019
    Assignee: PHARMAFILM S.R.L.
    Inventors: Francesco Cilurzo, Paola Minghetti, Luisa Montanari
  • Patent number: 10391139
    Abstract: Blood Pressure Reduction with Dietary Supplements Abstract A daily dose of 6,000 mg of taurine, 1,000 mg of vitamin C, 150 mg of grape seed extract, 100 mg of vitamin B6, 2 mg of biotin, 2,000 IU of vitamin D3, and 87 mg of magnesium is shown to reduce blood pressure in hypertensive individuals by more than 10 mm Hg.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: August 27, 2019
    Assignee: Biotics Research Corporation
    Inventors: William S. Sparks, Daryl L. De Luca, Denis R. De Luca, Mark Houston
  • Patent number: 10383980
    Abstract: The invention features a composition comprising a self-healing interpenetrating network hydrogel comprising a first network and a second network. The first network comprises covalent crosslinks and the second network comprises ionic or physical crosslinks. For example, the first network comprises a polyacrylamide polymer and second network comprises an alginate polymer.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 20, 2019
    Assignees: President and Fellows of Harvard College, Seoul National University Industry Foundation
    Inventors: Jeong-Yun Sun, Xuanhe Zhao, Widusha R. K. Illeperuma, Kyu H. Oh, Joost J. Vlassak, Zhigang Suo, Jianyu Li, David J. Mooney
  • Patent number: 10369118
    Abstract: A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 6, 2019
    Assignee: Cole Research & Design, LLC
    Inventor: Jeptha N. Cole
  • Patent number: 10342882
    Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 9, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Jose Manuel Mejia Oneto, Maksim Royzen
  • Patent number: 10328096
    Abstract: Composition comprising chitosan for use in the prevention and/or treatment of incontinence and/or impotence in a subject undergoing prostatectomy.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: June 25, 2019
    Assignees: UNIVERSITA' DEGLI STUDI DI TORINO
    Inventors: Thomas Freier, Stefano Geuna, Francesco Porpiglia
  • Patent number: 10293079
    Abstract: This invention provides a kit for making an adhesive and/or a sealant which includes: a first composition of alginate and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60, and a second composition of alginate and a buffer, wherein the buffer has a pH value of between 2 to 7. The invention also provides a method for making a sealant or an adhesive, by contacting the first composition and the second composition.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 21, 2019
    Assignee: SEALANTIS LTD.
    Inventors: Ohad Kimhi, Ronit Langzam-Sinai, Havazelet Bianco-Peled, Charles Milgrom, Rina Lev
  • Patent number: 10272156
    Abstract: A liquid composition which comprises an organic liquid diluent and at least one non-ionic cellulose ether having a viscosity of up to 2.33 mPa·s, measured as a 2 wt.-% solution in water at 20° C., is stable over an extended time period. The liquid composition is useful for preparing a solid dispersion comprising at least one active ingredient in at least one cellulose ether by spray-drying. Alternatively a solid dispersion can be produced by blending and extruding at least one active ingredient, at least one cellulose ether having a viscosity of up to 2.33 mPa·s and optionally one or more adjuvants.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: April 30, 2019
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Meinolf Brackhagen, Nicholas S. Grasman, Mark J. Hall, Steven J. Guillaudeu, Robert L. Schmitt, Matthias Knarr
  • Patent number: 10232087
    Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: March 19, 2019
    Assignee: LOCATE THERAPEUTICS LIMITED
    Inventors: Richard Melville France, Robin Andrew Quirk
  • Patent number: 10220047
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 5, 2019
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Patent number: 10208403
    Abstract: A viscose fiber comprises a fiber body including a regenerated cellulosic material and a plurality of microcapsules dispersed in the regenerated cellulosic material. The regenerated cellulosic material is derived from an organic plant material and the plurality of microcapsules containing a phase change material has a transition temperature in the range of 0° C. to 100° C., the phase change material providing thermal regulation based on at least one of absorption and release of latent heat at the transition temperature.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: February 19, 2019
    Assignee: OUTLAST TECHNOLOGIES, LLC
    Inventors: Mark Hartmann, James Brice Worley, Matthew North
  • Patent number: 10201576
    Abstract: The present invention discloses a herbal formulation comprising therapeutic effective amount of plant extract of Woodfordia Floribunda; therapeutic effective amount of plant extract of Centella Asiatica; and an effective amount of at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: February 12, 2019
    Assignee: Ultratech India Limited
    Inventor: Bhatia Rishi
  • Patent number: 10195252
    Abstract: The present invention provides microparticles that deliver in vivo predictable release profiles of at least one chemokine to create a biomimetic chemokine concentration gradient that induces the migration of multipotent stem cells to the anatomical site of the microparticles. Various release profiles are demonstrated that depend upon the relative concentration of alginate in the chemokine-loaded microparticle. Local administration and/or intraarticular injection of the microparticles are useful in conditions such as osteoarthritis. Targeted systemic delivery of the alginate chemokine microparticles to distant anatomical sites subjected to autoimmune disease symptomology can be performed by encapsulation within liposomes having targeting ligands. Consequently, upon the creation of the appropriate chemokine gradient, multipotent stem cells will migrate to the distant anatomical site where the liposomes are attached.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: February 5, 2019
    Assignee: University Of Pittsburgh—Of The Commonwealth System of Higher Education
    Inventors: Steven R. Little, Riccardo Gottardi, Mintai Peter Hwang, Daniel DeSantis
  • Patent number: 10179779
    Abstract: The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid. More particularly, the invention relates to polymorph forms of Polymorph Form I, Polymorph Form II, Polymorph Form III, Polymorph Form IV, Polymorph Form V, and Polymorph Form VI, and to processes for the preparation of, compositions containing and to uses of, such polymorph forms.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: January 15, 2019
    Assignee: RaQualia Pharma Inc.
    Inventors: Toyoharu Numata, Hideyuki Aoyama, Kaori Muraji
  • Patent number: 10172954
    Abstract: The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 8, 2019
    Assignee: MEDESIS PHARMA
    Inventors: Caroline Bauer, Elsa Compte, Olivier Gremy, Laurent Miccoli, Jaime Francisco Angulo-Mora, Jean-Claude Maurel
  • Patent number: 10154976
    Abstract: The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: December 18, 2018
    Assignee: Bordoloi Biotech, LLC
    Inventors: Binoy K Bordoloi, Nayan J Sarma, Rodney L. Eisenberg
  • Patent number: 10155824
    Abstract: A method of producing a carboxymethyl-group-containing modified hyaluronic acid and/or a salt thereof includes a step of subjecting, in a water-containing solvent having a temperature of 30° C. or less, a dissolved raw material hyaluronic acid and/or a salt thereof to a reaction with a haloacetic acid and/or a salt thereof, the water-containing solvent including water or a liquid mixture of a water-soluble organic solvent and water, a ratio of the water-soluble organic solvent in the liquid mixture being 60 v/v % or less.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: December 18, 2018
    Assignee: KEWPIE CORPORATION
    Inventors: Shunichi Fujikawa, Yukina Abe, Kazunori Asaoka, Takushi Yoshida
  • Patent number: 10154881
    Abstract: Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: December 18, 2018
    Assignee: Arizona Board of Regents for and on behalf of Arizona State University
    Inventors: Kaushal Rege, Huang-Chiao Huang
  • Patent number: 10130584
    Abstract: The purpose of the present invention is to provide a new disintegrative particulate composition having an optimal balance between the tablet hardness and disintegrability that are mutually opposing properties, and disintegrating tablets for pharmaceuticals and various kinds of foods comprising said composition. The present invention relates to a disintegrative particulate composition comprising milled lactose and/or granulated lactose as an excipient, and to a disintegrating tablet for pharmaceuticals or foods, comprising the disintegrative particulate composition, especially the tablet having tablet hardness of from 20 to 200 N, and disintegration time in water of from 1 to 60 sec.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: November 20, 2018
    Assignee: DAICEL CORPORATION
    Inventors: Takahiro Hiramura, Kiyoshi Ikura, Tomohito Okabayashi, Yoshihisa Takigawa, Naohiro Hashikawa
  • Patent number: 10130711
    Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: November 20, 2018
    Assignees: The Regents of the University of California, Alchemical Research Holdings, LLC
    Inventors: Jose Manuel Mejia Oneto, Ziyad F. Al-Rashid
  • Patent number: 10111838
    Abstract: A pharmaceutical or nutraceutical composition, contains a) a core a), containing a pharmaceutical or a nutraceutical active ingredient and b) a coating layer b), containing a mixture of 80 to 96% by weight of a water-insoluble (meth)acrylate polymer and 4 to 20% by weight of guar gum, wherein the water-insoluble (meth)acrylate polymer contains polymerized units of more than 95 and up to 100% by weight C1-C4-alkyl esters of acrylic acid or of methacrylic acid and less than 5% by weight of acrylic acid or methacrylic acid.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 30, 2018
    Assignee: Evonik Roehm GmbH
    Inventors: Shraddha Joshi, Ashish Guha, Vinay Jain
  • Patent number: 10104888
    Abstract: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: October 23, 2018
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jess Dreher Reed, Christian Gerald Krueger, Sergio Madrigal-Carballo
  • Patent number: 10093674
    Abstract: Disclosed are nucleopeptide compounds that include a nucleobase, and an amino acid. Certain compounds further comprise a glycoside. The compounds may self-assemble to form supramolecular hydrogels. Also, the compounds may be used as a platform to examine specific biological functions (e.g., binding to DNA and RNA) of a dynamic supramolecular system that is able to interact with both proteins and nucleic acids. Other uses include: methods of growing cells and methods of delivering a substance to a cell.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: October 9, 2018
    Assignee: Brandeis University
    Inventor: Bing Xu
  • Patent number: 10086113
    Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: October 2, 2018
    Assignee: LOCATE THERAPEUTICS LIMITED
    Inventors: Richard Melville France, Robin Andrew Quirk
  • Patent number: 10080715
    Abstract: The invention relates to a process for preparing polysaccharide-based microparticles with improved mechanical properties and hydrolytic stability. The spherical particles are useful as exfoliating agents in cosmetic formulations, in replacement of the newly banned plastic microbeads. The method comprises the preparation of hydrogel particles, drying of the particles, and a solid-state reaction that results in the covalent stabilization of the material. The invention also encompasses microparticles made using the method.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 25, 2018
    Assignee: Bowling Green State University
    Inventors: Giuseppe Giammanco, Alexis Ostrowski